GGAL vs JXN

The deterministic health profile is critically weak, highlighted by a Piotroski F-Score of 2/9 and a massive valuation gap where the current price ($47.93) trades at a significant premium to the Graham Number ($8.34) and Intrinsic Value ($6.23). While long-term price performance has been exceptional, current fundamentals show severe deterioration, including a negative YoY revenue growth of 10% and a catastrophic earnings surprise trend (-149.13% over the last 4 quarters). The dividend is unsustainable with a payout ratio of 123.58%, suggesting capital erosion. Despite bullish analyst targets, the hard data indicates a high-risk, overvalued asset.

JXN presents a classic 'value trap' profile, characterized by a critically weak Piotroski F-Score of 2/9 and an abysmal ROE of 0.71%. While the company is fundamentally undervalued from a balance sheet perspective—trading at a Price/Book of 0.82 and a Forward P/E of 4.44—the underlying operational health is poor. Strong recent price momentum and revenue growth are offset by razor-thin profit margins (0.40%) and bearish insider sentiment. The investment case relies entirely on a mean-reversion of book value rather than operational excellence.